Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

PureTech Health plc - American Depositary Shares (NQ:PRTC)

19.00 +0.20 (+1.06%)
Streaming Delayed Price Updated: 2:57 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PureTech Health plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders
From PureTech Health plc
Via Business Wire
Results of PureTech's Annual General Meeting
From PureTech Health plc
Via Business Wire
PureTech to Present at the Jefferies Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic
From PureTech Health plc
Via Business Wire
PureTech Health FY22 Revenue Declines 10.2% YoY, Here Are The Details
PureTech Health plc (NASDAQ: PRTC) (LSE:PRTC) released its results for the year ended December 31, 2022, revealing revenue of $15.6 million, a decrease of 10.2% compared to $17.4 million in 2021.... 
Via Benzinga
Earnings Scheduled For April 28, 2023
Companies Reporting Before The Bell • GrafTech International (NYSE:EAF) is likely to report quarterly loss at $0.01 per share on revenue of $123.00 million. 
Via Benzinga
PureTech Announces Annual Results for Year Ended December 31, 2022
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID
From PureTech Health plc
Via Business Wire
PureTech Health: Notice of Results
From PureTech Health plc
Via Business Wire
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
From Royalty Pharma plc
Via GlobeNewswire
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
From PureTech Health plc
Via Business Wire
PureTech to Present at the Barclays Global Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD)
From PureTech Health plc
Via Business Wire
PureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression
From PureTech Health plc
Via Business Wire
PureTech to Present at the SVB Securities Global Biopharma Conference
From PureTech Health plc
Via Business Wire
Why FARO Technologies Shares Are Trading Lower By 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 133.1% to $0.2870. Helbiz recently announced discontinuation of operations in non-profitable markets. 
Via Benzinga
Why Ontrak Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Ontrak, Inc. (NASDAQ: OTRK) shares jumped 101.7% to $1.1599 after the company announced new data that shows a reduction in depression and axiety symptoms for Ontrak Health's Wholehealth+... 
Via Benzinga
PureTech Provides End of Year Report on Key Progress
From PureTech Health plc
Via Business Wire
PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers
From PureTech Health plc
Via Business Wire
PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference
From PureTech
Via Business Wire
PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting
From PureTech Health plc
Via Business Wire
PureTech Founded Entity Sonde Health Raises $19.25 Million Series B for Voice-Based Health Monitoring
From PureTech Health plc
Via Business Wire
PureTech Announces New Therapeutic Candidate LYT-310, An Oral CBD Prodrug
PureTech Health plc (NASDAQ: PRTC) (LSE:PRTC) announced the nomination of a new therapeutic candidate, LYT-310, which is an oral CBD prodrug and the second therapeutic candidate developed from... 
Via Benzinga
PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform
From PureTech Health plc
Via Business Wire
PureTech to Present at Two Upcoming Investor Conferences
From PureTech Health plc
Via Business Wire
PureTech to Present at the Jefferies London Healthcare Conference
From PureTech Health plc
Via Business Wire
PureTech to Present at the Credit Suisse 31st Annual Healthcare Conference
From PureTech Health plc
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.